Proper evaluation of nuclear medicine diagnosis and treatment

Committee:
Medical Equipment
status:
Progress
Published:
A long-standing legal and regulatory double standard exists regarding the in-hospital production and delivery of positron emission tomography (PET) imaging agents used in PET scans, under both general law and the Pharmaceuticals and Medical Devices (PMD) Act. Additionally, while the reimbursement system previously covered PET imaging agents only through a bundled technical fee (due to the absence of an official drug price), a double standard has emerged with therapeutic PET imaging adjuncts, for which both a drug price and a separate technical fee for PET imaging have now been newly established.

Recommendations

  • PET examinations using PET diagnostic reagents are based only on previous applications for medical technology assessment proposals. The EBC proposes the establishment of a new medical fee system so that approval companies can apply for Insurance application for PET testing technology fees and diagnostic reagents.